THE PHENOTYPIC CHARACTERISTICS OF LEUKEMIA-ASSOCIATED MACROPHAGES ARE SHAPED BY ORGAN-SPECIFIC LEUKEMIC MICROENVIRONMENTS AND TARGETING IRF7-SAPK/JNK PATHWAY ELIMINATES THEIR PRO-LEUKEMIC EFFECTS

Guoguang Zheng,Xiao Yang,Wenli Feng,Rong Wang,Feifei Yang,Lina Wang,Qian Ren
DOI: https://doi.org/10.1016/j.exphem.2018.06.078
IF: 3.249
2018-01-01
Experimental Hematology
Abstract:Macrophages are indispensable cellular component in both innate immunity and adaptive immunity. Macrophages show great plasticity and can be specifically shaped by microenvironments in both homeostatic and pathological states. In tumor microenvironments, macrophages are educated to M2-like phenotypes, which are believed to have pro-tumor effects. Applications targeting M2-like tumor-associated macrophages (TAMs) improved outcome in various solid tumors. The significance of macrophages in hematopoietic malignancies was reported and leukemia-associated macrophages (LAMs) have been suggested. However, the phenotypic characteristics of LAMs in different leukemic microenvironments and whether in vivo targeting the LAMs could eliminate their pro-leukemic effects in leukemic microenvironments have not been established. In this study, we analyzed clinical relevance of macrophages in human acute myeloid leukemia (AML), studied phenotypic evolution of bone marrow (BM) and spleen (SP) LAMs in mouse AML and T cell acute lymphoblastic leukemia (T-ALL) models, explored mechanism leading to different LAM phenotypes and tried to eliminate pro-leukemic effects by reprogramming LAMs to have more M1-associated characteristics. The results showed that more CD163 positive M2-like LAMs but not CD68 positive total LAMs correlated with worse prognosis in AML patients. Heterogeneity of LAM activation in tissue-specific leukemic niches was observed in both AML and ALL models, i.e. in SP niche LAMs evolved with more M2 characteristics while in BM niche LAMs evolved with more M1 characteristics. Furthermore, IRF7 contributed to M1 characteristics through the activation of SAPK/JNK pathway. Moreover, targeting IRF7-SAPK/JNK pathway to induce more M1 characteristics in LAMs attenuated their pro-leukemic effects both in vitro and in vivo, and contributed to prolonged survival in leukemia mice. Our study provides the first evidence on how macrophages respond differently to different leukemic niche and the potential target for macrophage based immuno-therapy strategy against leukemia.
What problem does this paper attempt to address?